Abstract: The present invention relates to antibodies targeting Tumor Associated Macrophages (TAMs) and uses thereof. The inventors investigated specific marker exposed on the surface of the macrophages associated to tumor in order to detect and target TAMs. They showed that sideroflexin 3, which is absent in normal macrophage, is expressed by tumor associated macrophages. The inventors further demonstrated that using antibody directed to sideroflexin 3, they depleted TAMs in PBMC sample obtained from LCC patient, and strongly reduced leukemic B cells number.

Abstract: The present invention relates to antibodies targeting Tumor Associated Macrophages (TAMs) and uses thereof. The inventors investigated specific marker exposed on the surface of the macrophages associated to tumor in order to detect and target TAMs. They showed that sideroflexin 3, which is absent in normal macrophage, is expressed by tumor associated macrophages. The inventors further demonstrated that using antibody directed to sideroflexin 3, they depleted TAMs in PBMC sample obtained from LCC patient, and strongly reduced leukemic B cells number.

Abstract: The present invention relates to a TNF? blocking agent for use in the treatment and prevention of melanoma in a subject in whom melanoma cells express MHCI and in whom stroma cells exhibit TNF expression.

Abstract: The present invention relates to a TNF? blocking agent for use in the treatment and prevention of melanoma in a subject in whom melanoma cells express MHCI and in whom stroma cells exhibit TNF expression.

Abstract: The invention relates to a tissue binding composition. The inventive composition is characterised in that it comprises: between 40 g/l and 80 g/l trehalose, preferably approximately 60 g/l; between 40% and 80% (v/v) ethanol, preferably approximately 70% (v/v): between 0% and 5% (v/v) acetic acid, preferably approximately 1% (v/v); and between 20% and 60% (v/v) water, preferably approximately 29% (v/v).